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Host-derived extracellular 
RNA promotes adhesion of 
Streptococcus pneumoniae to 
endothelial and epithelial cells
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Streptococcus pneumoniae is the most frequent cause of community-acquired pneumonia. The 
infection process involves bacterial cell surface receptors, which interact with host extracellular matrix 
components to facilitate colonization and dissemination of bacteria. Here, we investigated the role of 
host-derived extracellular RNA (eRNA) in the process of pneumococcal alveolar epithelial cell infection. 
Our study demonstrates that eRNA dose-dependently increased S. pneumoniae invasion of alveolar 
epithelial cells. Extracellular enolase (Eno), a plasminogen (Plg) receptor, was identified as a novel 
eRNA-binding protein on S. pneumoniae surface, and six Eno eRNA-binding sites including a C-terminal 
15 amino acid motif containing lysine residue 434 were characterized. Although the substitution 
of lysine 434 for glycine (K434G) markedly diminished the binding of eRNA to Eno, the adherence 
to and internalization into alveolar epithelial cells of S. pneumoniae strain carrying the C-terminal 
lysine deletion and the mutation of internal Plg-binding motif were only marginally impaired. 
Accordingly, using a mass spectrometric approach, we identified seven novel eRNA-binding proteins 
in pneumococcal cell wall. Given the high number of eRNA-interacting proteins on pneumococci, 
treatment with RNase1 completely inhibited eRNA-mediated pneumococcal alveolar epithelial cell 
infection. Our data support further efforts to employ RNAse1 as an antimicrobial agent to combat 
pneumococcal infectious diseases.
Streptococcus pneumoniae is a Gram-positive bacterium, which is a main cause of community-acquired pneu-
monia (CAP). Initial treatment of CAP mostly includes antibiotic therapies1. However, pneumococcal antibiotic 
resistance has escalated dramatically over the last three decades making pneumonia a leading cause of death, 
especially among high-risk groups such as children under the age of five, elderly people, and immunocompro-
mised individuals2,3. An increasing number of penicillin and macrolide resistant isolates and also a continuous 
increase in multidrug resistance (MDR, resistant to ≥ 3 classes of antimicrobials) have been reported4. The inven-
tion of a 13th valent conjugate vaccine (Prevnar13®) has generated limited protection in children5. Due to the 
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restricted serotype coverage combined with the low vaccination status of the elderly and immunocompromised 
patients5, novel strategies against this pathogen are sorely needed.
In addition to the pore-forming cytotoxin pneumolysin and the phagocytosis-inhibiting polysaccharide cap-
sule, the virulence of S. pneumoniae is promoted by the capacity of bacteria to bind to and internalise into host 
cells and to spread into host tissue. All these processes require the involvement of bacterial cell wall-associated 
components, adhesins6. Adhesins bind to eukaryotic cell surface receptors7,8 or extracellular matrix (ECM) 
components9,10. They can be divided into two groups: cell-wall-anchored polypeptides8,11,12 and anchorless pro-
teins13–17. The last group is represented, among others, by the glycolytic enzyme enolase (Eno). Extracellular 
Eno is a surface-located plasminogen (Plg)-binding protein of S. pneumoniae17,18. It possesses two Plg-binding 
sites, one comprising C-terminal lysine residues (433KK434) and the second involving the amino acid sequence 
248FYDKERKVY256 17–19. The importance of Eno in the binding of Plg to bacterial surface was underscored by 
the reduced invasive potential of pneumococcal mutants expressing Eno with amino acid substitution in both 
Plg-binding motifs19.
Accumulating evidence suggests that intracellular macromolecules such as proteins and nucleic acids are 
released into the extracellular milieu where they may serve as alarmins and thus affect various host defence 
processes6,20. Extracellular nucleic acids were found to induce humoral and cellular immune responses during 
infection and to promote the formation of fibrin that entraps invading microbes20–22. In particular, host-derived 
eRNA was reported to: i) enhance fibrin deposition by the activation of the contact phase pathway22,23, ii) increase 
the adhesion and transmigration of leukocytes to and across the endothelium24, iii) and, augment the release of 
proinflammatory cytokines such as macrophage inflammatory protein-2, interleukin-1β , − 6, − 10, and tumor 
necrosis factor α from neutrophils, bone marrow-derived macrophages and endothelial cells24–27. However, the 
direct interaction of host-derived eRNA with pneumococcal surface, and the potential consequences of this pro-
cess on bacterial tropism have not been addressed thus far. Here, we propose that the eRNA facilitates bacterial 
adherence and invasion by serving as a “bridging molecule”, which connects bacterial cell surface-associated 
proteins with components of the host cell membrane. Consequently, administration of RNase1 can disrupt the 
invasion process and serves as a new anti-infectious agent.
Results
Extracellular RNA promotes pneumococcal infection of lung epithelial cells. In order to investi-
gate the role of eRNA in S. pneumoniae infection, we first tested whether eRNA associates with lung epithelial cell 
membrane. To this end, A549 cells were incubated with the different concentrations of biotinylated eRNA and 
its interaction with the cell membrane was examined by FACS. Flow cytometry analysis revealed a dose-depend-
ent binding of eRNA to epithelial cells (Fig. 1A). Next, to study the impact of eRNA on S. pneumoniae invasion 
of lung epithelial cells, adherence of bacteria to the cells in the absence or presence of eRNA was monitored. 
Preincubation of A549 cells with eRNA nearly doubled bacterial adhesion to A549 cells in a dose-dependent 
manner from 46.03 ± 9.9 adherent bacteria per cell without eRNA up to 76.64 ± 25 bacteria per cell with 10 μ g 
eRNA (Fig. 1B,C). In general, the internalization rate of pneumococci into A549 cells was low, however in the 
presence of eRNA this process was enhanced too (Fig. 1D). Similar results were obtained when human umbilical 
vein endothelial cells (HUVEC) and human pulmonary microvascular endothelial cells (HPMEC) were employed 
(Supplementary Fig. S1). In order to clarify the effect of eRNA-supplementation on bacterial internalization, anti-
biotic protection assays with a pneumolysin-deficient strain (SpΔply) were performed (Fig. 1E). Quantification 
of internalized bacteria by determination of cfu after plating revealed a three-fold increase in pneumococcal 
internalization from 1.1 ± 0.3 bacteria per cell up to 3.1 ± 1.0 bacteria per cell (Fig. 1E). Of note, no replication of 
bacteria during infection of A549 cells was observed (Supplementary Fig. S2). To test specificity of eRNA impact, 
human extracellular DNA (eDNA) was utilized, however, no effect of eDNA on bacteria invasion was observed 
(data not shown). To determine whether eRNA may directly bind to S. pneumoniae, bacteria (104–109 cfu) were 
immobilized on a membrane and incubated with biotinylated eRNA. As depicted in Fig. 1F, eRNA interacted 
with pneumococci in a dose-dependent manner. Interestingly, eRNA interacted not only with Gram-positive 
(S. pneumoniae 35 A, S. pneumoniae TIGR4, S. pyogenes, Staphylococcus aureus and Listeria monocytogenes), but 
also with Gram-negative (Neisseria meningitides and Escherichia coli) bacteria and the binding of eRNA to bacte-
ria was independent on the expression of pneumolysin (Sp35AΔply) (Supplementary Fig. S3). Altogether, these 
results indicate an important role of eRNA as a mediator of pneumococcal adhesion.
Pneumococcal Eno interacts with extracellular nucleic acids. A strong negative charge density 
associated with the RNA phosphate backbone favours interaction with positively charged protein domains28. 
Considering that bacterial cell wall-associated Eno possesses a highly positively charged (5.9 at pH 7.0) 
C-terminal region (K405-K434)17,29, we hypothesized that extracellular Eno becomes directly involved in the 
binding of eRNA to pneumococci. Indeed, the dot blot analysis revealed dose-dependent binding of biotiny-
lated eRNA to bacterial Eno (Fig. 2A). The solid-phase binding assay employing immobilized Eno confirmed a 
dose-dependent interaction between Eno and eRNA (Fig. 2B). Furthermore, the binding of biotinylated eRNA to 
Eno was completely abrogated when competing unlabeled eRNA was added in a 100-fold molar excess or when 
the lysine analog tranexamic acid (TXA) was applied (Fig. 2B). Interestingly, an association of Eno with eDNA 
was observed as well (Fig. 2C). Similar to eRNA, the binding of biotinylated eDNA to Eno was abolished when 
competing unlabeled eDNA was added in a 100-fold molar excess or when the TXA was utilized (Fig. 2C). Plg 
was used as a positive control for binding to Eno (Fig. 2D).
The Eno/nucleic acid interaction depends on the size of the nucleic acid fragments and on their 
nucleotide composition. In order to investigate whether the size of nucleic acid fragments may deter-
mine their binding ability to pneumococcal Eno, the nucleic acids were subjected to sonication (Fig. 3A,B). The 
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Figure 1. Pneumococcal infection is attenuated in the presence of eRNA. (A) A549 cells were incubated with 
different concentrations of biotinylated eRNA. After eRNA treatment cells were analysed by flow cytometry. Gate 
based on forward and side scatter was set to eliminate cellular debris and cell clusters (left panel). The binding 
of eRNA to cell membrane was analyzed in the Cy5 channel of the flow cytometer. Histogram overlay illustrates 
control cells (black), and cells incubated with 10 μ g biotinylated eRNA (red) or Cy5-conjugated Streptavidin (blue; 
middle panel). Dose-dependent binding of eRNA to A549 cells analyzed by flow cytometry (right panel). Data 
represent mean values (± SEM). n = 4, ***p ≤ 0.001 vs control (Ctrl). (B) Human lung pneumocytes A549 were 
preincubated with different doses of eRNA (0.01–10 μ g) and pneumococcal host-cell adherence and internalization 
of serotype 2 S. pneumoniae (Sp)-strain (ATCC11733) were measured by immunofluorescence staining and 
microscopy. The staining procedure resulted in Alexa568-labeled intracellular bacteria (red fluorescence) and 
Alexa488/568-labeled extracellular pneumococci (green/yellow). Scale bars in the images represent 10 μ m.  
(C) Quantification of pneumococcal adherence to A549 cells after treatment with different doses of eRNA. Data 
represent mean values ± SEM; n = 3; *p ≤ 0.05. (D) Quantification of pneumococcal internalization into A549 cells 
after eRNA treatment. Data represent mean values ± SEM; n = 3; **p ≤ 0.01; ***p ≤ 0.001. (E) The internalization of 
S. pneumoniae pneumolysin-deficient strain (SpΔ ply) into A549 cells measured by antibiotic protection assay. Data 
represent mean values ± SD; n = 3; *p ≤ 0.05, **p ≤ 0.01; ***p ≤ 0.001. (F) Different amounts of S. pneumoniae (104, 
105, 106, 107, 108 and 109 cfu) were immobilized on the nitrocellulose membrane. The binding of biotinylated eRNA 
to bacteria was detected using peroxidase-coupled streptavidin.
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maximal binding of eRNA to Eno was observed when eRNA was sheared to less than 500 ribonucleotide bases in 
length. Strikingly, longer sonication procedure generated smaller eRNA fragments that did not bind Eno effec-
tively (Fig. 3C). In regard to eDNA, the strongest interaction of eDNA with Eno was observed, when eDNA 
fragments were no longer than 500 deoxyribonucleotide bases (Fig. 3D). Next, to test the impact of nucleotide 
composition on the binding of nucleic acids to Eno, synthetic oligonucleotides (polydIdC, AU, polyC, polyIC, 
GC) were applied. A filter-binding assay revealed association of Eno with polydIdC, AU, polyC, polyIC, eRNA 
and eDNA (Fig. 3E,F). The binding of Eno to GC was also observed, however, it was less pronounced (Fig. 3E,F). 
Ethidium bromide staining demonstrated equal immobilisation of oligonucleotides on a nylon membrane (data 
not shown).
Altogether, our data indicate that the binding of Eno to extracellular nucleic acids depends on their size and 
nucleotide composition.
S. pneumoniae Eno possess multiple eRNA-binding sites. In order to map the eRNA-binding sites, 
the entire pneumococcal Eno sequence was divided into 141 overlapping synthetic peptides, each consisting of 
15 amino acids, with an offset of three amino acids19. The synthetic peptides were assayed for their capability to 
bind eRNA (Fig. 4A). The dot blot analysis using biotinylated eRNA revealed six potent eRNA-binding motifs: 
59RYGGLGTQK67, 104KGKLGA109, 188HALKKILKSRGLETA202, 312GKKVQL317, 401RTDRIAK408 and 432LKK434 
within Eno sequence (Fig. 4A–C). Interestingly, 401RTDRIAK408 and 432LKK434 motifs overlap with the C-terminal 
Plg-binding region17. Aforementioned peptides contain positively charged lysine and arginine residues contrib-
uting to their net positive charge ranging from 1.9 to 2.9. Next, the Protein Data Bank entry 1W6T was used to 
localize the identified eRNA-binding motifs in each monomer of the octamer structure of the pneumococcal 
Eno30. The putative eRNA-binding sequences were found to be distributed on each of the eight monomers of 
the Eno octamer on both, the front site and the backside (Fig. 4D–F). In line with previously published observa-
tions30, 401RTDRIAK408 and 432LKK434 motifs were found to be hidden in a structure of the protein and thus poorly 
accessible (Fig. 4D–F). Nevertheless, the eRNA-binding motif 312GKKVQL317 was found in close proximity to the 
C-terminal located lysines and thus may expand the eRNA-interacting surface (Fig. 4D,E).
Mutation of the Eno C-terminal lysine 434 to glycine reduces binding of Eno to eRNA. 
Regardless of their accessibility, C-terminal lysine residues of pneumococcal Eno seem to play a significant role 
in the recruitment of bacterial surface proteolytic activity and thus in host tissue invasion in vivo17,31,32. Hence, 
we investigated whether a mutation of lysine residue 434 within Plg-binding site of Eno may impair also its 
association with nucleic acids. A slot-blot filter binding assay demonstrated dose-dependent binding of eRNA to 
wild-type (wt) Eno (Fig. 5A). Substitution of lysine 434 with glycine (EnoK434G) markedly reduced the eRNA bind-
ing ability of Eno (Fig. 5A). Efficient binding of eDNA to wt Eno and a marked reduction in Eno binding ability 
Figure 2. Extracellular RNA interacts with pneumococcal Eno. (A) Different amounts of recombinant 
S. pneumoniae Eno (0.32, 0.65, 1.25, 2.5, 5 and 10 μ g) were spotted on a nitrocellulose membrane. The Eno/
eRNA interaction was tested using biotinylated eRNA and peroxidase-coupled streptavidin. (B) Five μ g of 
S. pneumoniae Eno were immobilized onto a microtiter plate and incubated with different concentration of 
biotinylated eRNA (● ) in the presence or absence of unlabeled eRNA (▲ ) and tranexamic acid (TXA) (○ ). 
(C) Eno was incubated with different concentration of biotinylated eDNA (● ) in the presence or absence of 
unlabeled eDNA (▲ ) and tranexamic acid (TXA) (○ ). (D) Eno was incubated with different concentrations of 
biotinylated plasminogen (Plg) (● ) in the presence or absence of unlabeled Plg (▲ ) and TXA (○ ). Data represent 
mean values ± SEM; n = 3; ###p ≤ 0.001; ***p ≤ 0.001 vs biotinylated eRNA/eDNA/Plg (● ).
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of K434G mutant were observed as well (Fig. 5A). As binding of Plg to Eno strongly depends on K434, Plg was 
used as a positive control (Fig. 5A). To confirm results obtained by the slot-blot filter binding assay, a solid-phase 
binding assay was performed (Fig. 5B–D). Here, a microtiter plate was coated with wt Eno, EnoK434G or BSA and 
increasing concentrations of nucleic acids were applied. While the efficient binding of eRNA and eDNA to wt Eno 
was observed, the interaction of EnoK434G with nucleic acids was severely impaired (Fig. 5B,C). As expected, the 
K434 substitution with glycine abolished also the Plg/Eno interaction (Fig. 5D).
Taken together, our data provide the evidence that C-terminal lysine residue 434 of Eno is important for its 
interaction with extracellular nucleic acids.
Extracellular RNA-dependent S. pneumoniae invasion is not affected by the deletion of 
C-terminal lysine residues and the mutation of Eno internal Plg-binding motif. To study the 
importance of eRNA-binding motifs within Eno on the eRNA-triggered bacterial invasion, a S. pneumoniae strain 
carrying deletion of the C-terminal lysines (433KK434) and amino acid substitutions in the internal Plg-binding 
motif (K251L, E252G and K254L) of Eno (Spenoint/del) was employed19. As a control, S. pneumoniae overexpress-
ing wt Eno (Spenowt) was utilized19. A549 cells were infected with both bacterial strains and their adherence to 
A549 cells and internalization was quantified (Fig. 6A and B, respectively). Spenowt strain demonstrated increased 
adherence to and internalization into A549 cells in the presence of 10 μ g of eRNA (Fig. 6A,B). However, the 
eRNA-mediated adherence of Spenoint/del to A549 cells was only slightly diminished as compared to the Spenowt 
strain (Fig. 6A). In addition, only a moderate tendency towards reduction in internalization of Spenoint/del into 
A549 cells as compared to Spenowt strain was noted (Fig. 6B). As reassociation of soluble Eno protein to bacte-
rial surface was previously reported17, bacteria were preincubated with soluble Eno protein in order to restore 
Eno-dependent binding capacity of Spenoint/del (Fig. 6A,B). Only, in the absence of eRNA or in the presence of 
0.1 μ g eRNA, pretreatment of Spenoint/del with Eno protein (Spenocompl) resulted in increased bacterial adherence 
(Fig. 6A). No significant differences in Spenocompl internalization into A549 cells as compared to Spenoint/del were 
noted (Fig. 6B).
In summary, the deletion of C-terminal lysine residues and the mutation of internal Plg-binding motif only 
marginally impaired S. pneumoniae adherence and internalization pointing to the role of other Eno eRNA-binding 
sites in bacteria invasion or the existence of additional eRNA-binding proteins on S. pneumoniae surface.
Figure 3. Eno/eRNA interaction depends on the size of the nucleic acids and on their nucleotide composition. 
(A,B) Total RNA and DNA were isolated from human A549 cells and subjected to different sonication times (1–12 s). 
Resulted eRNA (A) and DNA (B) was resolved on the agarose gel. (C) The binding of eRNA to pneumococcal 
Eno was determined using the solid-phase binding assay. Five μ g of immobilized Eno were incubated with 10 μ g 
sonicated eRNA. Eno/eRNA complexes were detected by chemiluminescence. Data represent mean values ± SEM; 
n = 3; **p ≤ 0.01; *p ≤ 0.05 vs control; ##p ≤ 0.001 vs 10 s of sonication. (D) The binding of eDNA to pneumococcal 
Eno was determined using the solid-phase binding assay. Five μ g of immobilized Eno were incubated with 10 μ g 
sonicated and biotinylated eDNA. Eno/eDNA complexes were detected by chemiluminescence. Data represent mean 
values ± SEM; n = 3; ***p ≤ 0.001 vs control. (E) Five  μ g of synthetic oligonucleotides (polydIdC, AU, polyC, polyIC, 
GC), eRNA and eDNA were immobilized on the nitrocellulose membrane and their binding ability to biotinylated 
pneumococcal Eno was tested by dot blot. (F) Densitometry of (E). Data represent mean values ± SEM; n = 3.
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Figure 4. Identification and localization of eRNA-binding regions of Eno protein. (A) The entire 
pneumococcal Eno protein was divided into 141 overlapping peptides, each consisting of 15 amino acids, with 
an offset of three amino acids. The synthetic peptides were assayed for their ability to bind eRNA using dot 
blot analysis. (B) Sequences of spots (A18-A20, B7-B10, C10-C15, D9-D10, D25-E4, F5-F10 and F16) and 
the binding reactivity to biotinylated RNA. + , weak binding; + + , moderate binding; + + + , strong binding. 
(C) Densitometry of (A). (D–F) Extracellular RNA-binding motifs on the surface of the pneumococcal Eno 
octamer. Six eRNA-binding regions in the Eno octamer are depicted in green (59RYGGLGTQK67), yellow 
(104KGKLGA109), light green (188HALKKILKSRGLETA202), orange (312GKKVQL31), magneta (401RTDRIAK408) 
and blue (432LKK434). Front view (D), backside view (E) and side view (F). Internal Plg-binding motif of Eno 
(248FYKERKVY256) is depicted in red. The figure was generated using PyMol (DeLano Scientific LLC).
www.nature.com/scientificreports/
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Extracellular eRNA-binding proteins are expressed on S. pneumoniae surface. To identify other 
cell wall-associated proteins that interact with eRNA, protein wall fraction of S. pneumoniae was isolated and 
subjected to proteomic analysis (Fig. 7A). Cell wall proteins were separated using 2-D gel electrophoresis and 
eRNA-bound proteins were identified by MALDI-TOF MS. This approach revealed seven eRNA-binding proteins 
on the pneumococcal surface including: elongation factor Tu (EFTu; spots 1 and 2), ATP synthase subunit alpha 
(ATPα ; spot 2), 6-phospho-beta-glucosidase (BglA3; spot 2), maltose/maltodextrin ABC transporter (MalABC; 
Figure 5. Mutation of Eno C-terminal lysine 434 reduces Eno-eRNA/eDNA interaction. (A) Bovine serum 
albumin (BSA), wt pneumococcal Eno (Eno) and Eno mutant (EnoK434G) were spotted on the nitrocellulose 
membrane. The binding of proteins to eRNA, eDNA and Plg was tested by dot blot. Commassie brilliant blue 
(CBB) staining was used as a loading control. (B) The binding of pneumococcal Enowt (● ), EnoK434G (▲ ) or BSA 
(○ ) to eRNA was determined using the solid-phase binding assay. Immobilized proteins were incubated with 
different concentration of biotinylated RNA. Eno/eRNA complexes were detected by chemiluminescence.  
(C) The binding of pneumococcal Enowt (● ), EnoK434G (▲ ) and BSA (○ ) to eDNA was determined using the 
solid-phase binding assay. The immobilized proteins were incubated with different concentration of biotinylated 
eDNA. Eno/eDNA complexes were detected by chemiluminescence. Data represent mean values ± SEM; 
n = 3; ###p ≤ 0.001; ***p ≤ 0.001 vs wt Eno (● ). (D) The binding of Enowt (● ), EnoK434G (▲ ) or BSA (○ ) to Plg 
was determined using the solid-phase binding assay. Immobilized proteins were incubated with different 
concentration of biotinylated Plg. Eno/Plg complexes were detected by chemiluminescence. Data represent 
mean values ± SEM; n = 3; ###p ≤ 0.001; ***p ≤ 0.001 vs wt Eno (● ).
Figure 6. Pneumococcal Eno mutants lacking C-terminal eRNA-binding motif do not demonstrate reduced 
adherence to and internalization into A549 cells. (A,B) A549 cells were preincubated with different amounts of 
eRNA and infected with S. pneumoniae overexpressing wt Eno (Spenowt) or lacking C-terminal eRNA-binding motif 
(Spenoint/del). In rescue experiments Spenoint/del was preincubated with soluble Eno protein (Spenocompl). Pneumococcal 
host-cell adherence (A) and internalization (B) were determined by immunofluorescence staining and microscopy. 
Data represent mean values ± SEM; n = 3; *p ≤ 0.05 vs Spenoint/del; ***p ≤ 0.001 vs untreated A549 cells.
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spot 3), Eno (spot 3), cell division protein DivA (spot 4), DNA-directed RNA polymerase subunit alpha (RNAPα , 
spot 5) (Fig. 7B). Interestingly, Eno exhibited a moderate eRNA binding capacity as compared to EFTu, ATPα and 
BglA3, which manifested more pronounced interactions with eRNA (Fig. 7A, left panel).
RNase1 treatment inhibits eRNA-triggered S. pneumoniae invasion. In order to confirm the 
eRNA-mediated effect on pneumococcal adherence and invasion, eRNA-preincubated lung epithelial cells were 
treated with 1 ng or 10 ng RNase1 prior to the infection with SpΔply pneumococci. A three-fold increase in 
bacterial adherence was determined after preincubation of A549 cells with 5 μ g of eRNA resulting in a relative 
amount of 30.2 ± 2.2 bacteria per cell versus only 10.4 ± 0.6 attached bacteria per cell without eRNA (Fig. 8A). 
Treatment of A549 cells with 1 ng RNase1 reduced eRNA-mediated pneumococcal attachment down to 13.6 ± 1.2 
adherent bacteria per cell (Fig. 8A). Incubation of eRNA-treated A549 cells with 10 ng RNAse1 completely neu-
tralized the supporting effect of the eRNA on bacterial adherence. Similar results were obtained for the amount 
of internalized bacteria, although internalization rates in general were below 1 bacteria per cell (Fig. 8B). In order 
Figure 7. Identification of eRNA-binding proteins associated with pneumococcal wall. (A) Two hundred 
fifty μ g of cell wall proteins isolated from S. pneumoniae serotype 2 strain (ATCC11733), were resolved using 
two-dimensional gel electrophoresis. Polyacrylamide gels were simultaneously subjected to Western blotting 
using biotinylated eRNA (left panel) and to flamingo fluorescent gel stain (right panel). (B) List of proteins 
identified by MALDI-TOF analysis.
Figure 8. Extracellular RNA-mediated pneumococcal infection is diminished after RNase1 treatment. 
(A,B) A549 cells were preincubated with eRNA (5 μ g) and infected with SpΔply pneumococci in the absence or 
presence of RNase1 (1 and 10 ng). Pneumococcal host-cell adherence to (A) and internalization (B) into A549 
cells were tested using antibiotic protection assay. Data represent mean values ± SEM; n = 3; **p ≤ 0.01.
www.nature.com/scientificreports/
9Scientific RepoRts | 6:37758 | DOI: 10.1038/srep37758
to quantify the bacterial internalization, the amount of internalized bacteria per 2 × 105 cells was analyzed by 
antibiotic protection analyses. The counted cfu of invaded pneumococci revealed an up to 10-fold higher inter-
nalization rate after eRNA preincubation as compared to eRNA-free A549 cells (Fig. 8B). Incubation of A549 
cells with 1 and 10 ng RNase1 completely abolished promoting effect of eRNA on S. pneumoniae internalization 
(Fig. 8B). No impact of RNase1 on A549 viability was observed (data not shown). These results imply that RNase1 
may markedly diminish eRNA-mediated invasion of S. pneumoniae and confirm the role of eRNA as cofactor in 
pneumococcal adherence and internalization.
Discussion
In the current study we described the impact of extracellular host-derived RNA on the pneumococcal path-
ogenicity. Here, we provide compelling evidence that eRNA significantly promotes S. pneumoniae adhesion 
to and internalization into different host cells including HUVEC, HPMEC and A549 cells. The mechanism 
involves direct interaction of eRNA with bacterial cell wall-associated proteins to serve as a bridging factor 
between bacteria and host cells. Using a mass spectrometry approach novel eRNA-binding proteins potentially 
involved in eRNA-mediated pneumococcal invasion were identified. We demonstrated, for the first time, that 
Eno, a well-characterized Plg-receptor, strongly interacts with eRNA and identified multiple eRNA-binding sites: 
59RYGGLGTQK67, 104KGKLGA109, 188HALKKILKSRGLETA202, 312GKKVQL317 and 432LKK434 within the Eno 
sequence. Interestingly, 432LKK434 motif is involved in interaction with Plg as well17,18. Although, substitution of 
lysine 434 with glycine (K434G) markedly diminished the binding of eRNA to Eno, the adherence to and inter-
nalization into alveolar epithelial cells of S. pneumoniae strain carrying the C-terminal lysine deletion and the 
mutation of internal Plg-binding motif were not significantly impaired. Consequently, proteomic analysis of cell 
wall fraction of S. pneumoniae identified, in addition to Eno, several surface-associated eRNA-binding proteins. 
These include: EFTu, ATPα , BglA3, MalABC, DivA, and RNAPα . Interestingly, treatment with RNase1 com-
pletely inhibited eRNA-mediated pneumococcal adherence to and internalization into alveolar epithelial cells. 
Together, these data indicate that eRNA represents a novel virulence cofactor promoting pneumococcal invasion 
and that treatment with RNase1 may provide a novel therapeutic option for patients with pulmonary infectious 
diseases.
Adhesion of bacteria to host tissue is an essential step in microbial colonization and the development of com-
plex prokaryotic communities. It is also a prerequisite for the majority of infectious diseases6. Bacteria utilize 
adhesins to bind to eukaryotic cell surface receptors and ECM6, which is composed of proteoglycans as well as 
fibrous (among others fibronectin, collagen, elastins and laminins) and matricellular (vitronectin and TSP-1) 
proteins33–35. Immobilized laminin, fibronectin and collagens were shown to interact with the bacterial proteins 
such as pneumococcal adherence and virulence factor B (PavB) and the tip of the pneumococcal pilus-1 struc-
ture (RrgA), leading to effective positioning of the bacteria and invasion of adjacent epithelial cells6. It was also 
demonstrated that human TSP-1 is recruited to the S. pneumoniae surface via bacterial peptidoglycan, and it can 
be exploited as a molecular bridge between bacterium and host cell9,36. Moreover, pneumococci engage ECM 
vitronectin to adhere to host α ν β 3 integrins, promoting bacterial internalization37. In the current study, we pro-
pose that host-derived nucleic acids, in particular eRNA, which are released from epithelial cells in response 
to infectious mediators, may potentiate S. pneumoniae colonization by increasing bacterial invasive properties. 
The mechanism involves the binding of eRNA to pneumococcal cell wall components, among which Eno was 
previously identified as a nucleic acid-binding protein38. Our data revealed that the binding of the eRNA to the 
EnoK434G mutant was markedly attenuated as compared to wt Eno. This suggests that eRNA may share the 
C-terminal binding motif with Plg, most likely without affecting Eno-mediated recruitment of Plg of S. pneumo-
niae, since Eno may also interact with Plg by internal Plg-binding region (248FYDKERKVY256)39. Interestingly, 
results of our protein binding assays demonstrate that the pneumococcal Eno binds not only eRNA, but also 
eDNA. However, incubation of eukaryotic cells with eDNA had no significant effect on bacterial adherence. 
This result may be explained by the presence of DNA-specific ribonucleases on bacterial surface. Pneumococci 
express eDNA-cleaving endonucleases to promote bacterial escape from neutrophil extracellular traps40. Thus, the 
eDNA-specific nuclease activity may neutralize the effect of eDNA on bacterial invasion.
Surprisingly, the deletion of the C-terminal lysine residues and the mutation of the internal Plg-binding 
region had almost no impact on eRNA-driven bacterial adhesion and internalization. This indicates that either 
other eRNA-binding motifs of Eno are involved in eRNA-triggered pneumococcal invasion or bacterial cells 
surface exposes other eRNA-binding proteins, which effectively compensate for the lack of Eno. Our proteomic 
analysis revealed seven potent eRNA-binding proteins. Interestingly, some of these proteins share similarities 
with bacterial Eno. For instance, RNAPα and  BglA3 possess C-terminal lysine residues. Although C-terminal 
lysine residue is absent in EFTu, this protein has been identified as a Plg receptor41–43. Instead of C-terminal 
lysines, it seems that EFTu/Plg interaction occur via internal amino acid regions (179LKALEGDSHYEDIV192 and 
249VGIKEETQKAV259). Prediction analysis of these fragments revealed that the amino acid charge meets the 
requirements for the interaction with lysine-binding sites of the Plg-kringle domains (S. Bergmann, unpublished 
data). Apart from Plg binding, cytoplasm-localized EFTu regulates protein synthesis and cellular metabolism 
by binding to and transporting amino-acyl-tRNA to the ribosomes confirming its RNA-binding ability44. Since 
EFTu, similarly to Eno, is associated with the cell wall of various bacteria41–43, it is imaginable that other cytosolic 
proteins such as RNAPα and/or BglA3 may also be transported to the bacterial surface thereby acting as “moon-
lighting proteins” for eRNA-binding at certain steps of the growth phase.
As a consequence of pneumococcal infection followed by cellular disruption sustained during acute lung 
injury, nucleic acids may be liberated to the lung parenchyma20,45,46. Increased level of eRNA was demonstrated 
in bronchoalveolar lavage fluids of patients suffering from acute respiratory distress syndrome (ARDS)47. This 
eRNA may participate in ARDS pathogenesis by increasing permeability of epithelia-capillary barrier48, enhanc-
ing intraalveolar fibrin deposition22,23,47,49 and stimulating the production and release of proinflammatory cytoki
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nes22,23,26,27,49. Here, we propose a novel function of eRNA, which promotes S. pneumoniae infection and the devel-
opment of pneumonia, a well-described direct cause of ARDS50. Given the relative high number of eRNA-binding 
proteins on pneumococcal surfaces, the best strategy to reduce eRNA-driven infection is to eliminate the excess 
of eRNA, rather than target one specific eRNA-binding protein. RNase is a natural counterpart of RNA in the vas-
cular system20. Several RNases possess diverse types of antimicrobial properties. However, it is unclear whether 
the killing of pathogens requires their intact enzymatic activity. From one hand, it was demonstrated that inhibi-
tion of ribonuclease activity strongly suppressed antifungal properties of RNase5 and RNase751, but on the other 
hand, studies using a ribonuclease-inactive recombinant RNase7 revealed that RNase7 activity is not essential 
for killing Gram-negative and Gram-positive bacteria including P. aeruginosa and S. pneumoniae52–54. The ability 
to bind to bacterial surface and to permeabilize the bacterial membrane seems to be crucial in antimicrobial 
action of many RNases52,53. This mechanism, however, does not apply to RNase1 activity against S. pneumoniae, 
since our results did not show any influence of RNase1 on bacterial survival. Thus, it is imaginable that the 
RNase1-mediated degradation of eRNA, a new adhesin, is partially responsible for anti-pneumococcal properties 
of this ribonuclease. Regardless of the mechanism, our in vitro data demonstrate that RNase1 treatment leads 
to the significant inhibition of S. pneumoniae adhesion to and internalization into alveolar epithelial cells and 
suggest that RNase1 may prevent the bacterial colonization in the lung. RNase1 has been successfully used as 
effective tissue-protective regimen in several animal models of human diseases. For instance, the administration 
of the RNase1 significantly reduced thrombus formation, prevented stroke and diminished the development of 
brain oedema48. Furthermore, RNase1 inhibited neointima development in an atherosclerotic mouse model55, 
and, in addition, conferred cardiac protection against ischaemia/reperfusion26,56,57. In subcutaneous xenograft 
models of human cancer, RNase1 strongly counteracted the tumorigenic activities of eRNA25. However, further 
studies utilizing murine model of pneumococcal infection are needed to validate whether the administration of 
RNase1 may prevent the development of S. pneumoniae-driven infection diseases.
In summary, we demonstrate for the first time that eRNA potentiates S. pneumoniae infection of alveolar 
epithelial cells. Since treatment with RNase1 inhibited eRNA-triggered S. pneumoniae invasion, our data support 
further efforts to employ RNAse1 as an antimicrobial agent to combat pneumococcal infectious diseases.
Methods
Materials. The His6-tagged S. pneumoniae Eno and EnoK434G were expressed in the Escherichia coli host strain 
M15 (pREP4) and protein purification was performed as previously described17. Lys-Plg was purchased from 
Chromogenix (Mölndal, Sweden), tranexamic acid (TXA) from Sigma-Aldrich (Taufkirchen, Germany) and t-PA 
from American Diagnostica (Pfungstadt, Germany). Recombinant bovine RNase1 and serum albumin (BSA) 
were purchased from Fermentas/Thermo Scientific (Schwerte, Germany) and from Sigma Aldrich, respectively.
Streptococcus strains and media. Streptococcus pneumoniae strains were cultured in Todd-Hewitt broth 
(Oxoid, Basingstoke Hampshire, UK) supplemented with 0.5% yeast extract (THY) to mid log phase or were 
cultured on Colombia blood agar plates containing 5% sheep blood (Becton Dickinson, Heidelberg, Germany). 
A low encapsulated serotype 2 pneumococcus (ATCC 11733) and isogenic Eno mutants were employed in cell 
culture infection experiments17. Pneumococcal mutants expressing Eno, lacking Plg-binding sites, were generated 
via site-specific deletion-insertion mutagenesis using the genetic background of the serotype 2 strain (ATCC 
11733) carrying the gene for erythromycin resistance17. The strain Spenoint/del carries a deletion of the C-terminal 
lysines (433KK434) and amino acid substitutions in the internal Plg-binding motif (K251L, E252G and K254L) 
of Eno19. The isogenic mutant Spenowt overexpresses wt Eno and was used as control. A pneumolysin-deficient 
serotype 35 A/47 mutant strain (SpΔply) was employed in some cell culture infection analysis to exclude 
pneumolysin-dependent effects on cell viability during assay conduction. The mutants were cultured on media 
supplemented with 5.0 μ g/ml erythromycin.
Cell culture. Human lung alveolar epithelial cells type II pneumocytes (A549 cells, ATCC CCL-185) were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) with low glucose (Invitrogen Life Technologies, Carlsbad, 
CA), supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS; Hyclone, Cramlington, UK) and 
2 mM L-glutamine (Invitrogen Life Technologies) at 37 °C and 5% CO2.
Binding of eRNA to enolase peptides synthesized on a cellulose membrane. A membrane with 
141 spot-synthetized peptides, derived from the Eno amino acid sequence, consisting of 15 amino acids each with 
an offset of three amino acids, was prepared as previously described19. eRNA binding was performed according to 
a standardized protocol as previously reported58. In brief, the membrane was incubated for 7 h with blocking buffer 
(Genosys Biotechnologies, London, UK) followed by overnight incubation with 5 μ g biotinylated eRNA diluted 
in blocking buffer. After washing, the membrane was incubated for 2 h with peroxidase-conjugated Streptavidin 
(Dako, Glostrup, Denmark). Finally, eRNA binding to peptides was detected using Chemiluminescence Reagent 
Plus substrate (Thermo Scientific) and a Kodak Image Station 2000 R. Quantitative densitometry analysis was 
performed using 1D gel analysis software LabImage 1D (Intas, Goettingen, Germany).
Binding of RNA, DNA and plasminogen to pneumococcal enolase. The extraction of RNA from 
A549 cells was performed using QIAzolTM lysis reagent (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. Genomic DNA was isolated from A549 cells using Genomic DNA Kit (Qiagen) following the 
manufacturer’s instructions. For fragmentation of nucleic acids, 1 mg of biotinylated RNA or DNA was dissolved 
in 1 ml of RNase-, DNase-free water and sonicated for 2, 4, 6, 8, 10, or 12 s. At the indicated time points, 100 μ l 
samples were withdrawn, and nucleic acids were precipitated with ethanol. The RNA and DNA were dissolved in 
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RNase- and DNase-free water and tested for Eno-binding capacity. Parallel samples were subjected to agarose gel 
electrophoresis and visualized by ethidium bromide staining.
The nucleic acid/Eno-binding activity was assessed by a filter-binding assay, where a nylon membrane was 
soaked with buffer A [10 mM Tris-Cl (pH 7.5), 50 mM NaCl, 1 mM EDTA, and 1× Denhardt’s solution (0.02% 
(m/v) Ficoll, 0.02% (m/v) polyvinylpyrrolidone, and 0.02% (m/v) BSA)] and fixed into a slot-blot apparatus47. 
Increasing concentrations (0–6 μ g/ml) of wild-type Eno (Enowt), Eno variant (EnoK434G) or BSA were applied to 
the filter in 100 μ l of Tris-buffered saline (TBS) for 15 min, and then aspirated through the filter and cross-linked 
for 10 min by exposure to ultraviolet light (254 nm). After washing with buffer A, the filter was incubated with 
either 10 μ g/ml of biotinylated eRNA, 3 μ g/ml of biotinylated eDNA or 10 μ g/ml Plg. Subsequently, the filter was 
washed and finally incubated with peroxidase-labeled streptavidin (DAKO). Detection of eRNA, eDNA and Plg 
was accomplished using enhanced chemiluminescence (Thermo Scientific). Biotinylation of RNA and DNA was 
performed with EZ LinkTM Psoralen-PEO-biotin (Thermo Scientific) according to the manufacturer’s instruc-
tions. Plg was biotinylated using the EZ-LinkTM Sulfo-NHS-Biotinylation Kit (Thermo Scientific)59.
A microtiter plate was coated with Eno, Eno variant (EnoK434G) or BSA (6 μ g/ml each) in 50 nM NaHCO3, pH 
9.6, and incubated at 4 °C overnight. The plate was washed three times with Tris-buffered saline (TBS; 150 mM 
NaCl, 20 mM Tris, pH 7.5) containing 0.1% Tween (TBS-T) buffer, and nonspecific binding sites were blocked with 
3% (m/v) BSA in TBS-T at room temperature for 1 h. Increasing concentrations of biotinylated Plg (0–25 μ g/ml), 
eRNA (0–25 μ g/ml) or eDNA (0–1 μ g/ml) in TBS were added to the wells and biotinylated molecules were 
allowed to bind to the Enowt, EnoK434G or BSA at room temperature for 2 h. After extensive washing with TBS, 
bound Plg, eRNA or eDNA were detected using a peroxidase-labeled streptavidin. Final detection was performed 
using 3,3′ ,5,5′ tetramethylbenzidine (TMB), with a TMB substrate kit (Thermo Scientific) according to the man-
ufacturer’s instructions.
Infection experiments and quantification of pneumococcal adherence and internalization into 
host cells by immunofluorescence staining and microscopy. eRNA-mediated bacterial adherence 
was quantified by counting the amount of bacteria attached to host cells after differential immunofluorescence 
staining of the pneumococci as previously described29. The impact of Eno/eRNA interaction on pneumococcal 
adherence was studied using a serotype 2 S. pneumoniae strain (ATCC11733) and isogenic enolase mutants17. 
Quantification of internalized bacteria was performed by antibiotic protection assay as previously described29. 
For details, please refer to the supplement.
Fractionation of pneumococcal cell wall proteins. Cell wall proteins from a serotype 2 S. pneumoniae 
strain (ATCC1173) were isolated by sequential fractionation as previously described17. For details, please refer to 
the supplement.
Determination of net peptide charge. Protein Calculator v3.4, developed by Chris Putnam at the Scripps 
Research Institute (www.scripps.edu/~cdputnam/protcalc), was used to calculate the net charge at physiological 
pH (7.4) for different peptide sequences.
Identification of eRNA binding proteins in S. pneumoniae cell wall fraction. For two-dimensional 
(2-D) gel electrophoresis 250 μ g of cell wall proteins isolated from S. pneumoniae, a serotype 2 strain 
(ATCC11733), were used. Protein separation in the second dimension was performed by electrophoresis on 
12.5% SDS polyacrylamide gels. Electrophoresis was carried out in a Hoefer 600 system. The matrix-assisted laser 
desorption/ionization mass spectrometry-time of light mass spectrometry (MALDI-TOF-MS) was performed on 
an Ultraflex TOF/TOF mass spectrometer equipped with a nitrogen laser and a LIFT-MS/MS facility. For details, 
please refer to the supplement.
Flow cytometry. A549 cells were seeded into 6-well tissue culture plates at a density of 2 × 105 cells/well. 
Next day, cells were wasched with PBS and incubated with 0.1, 1, 5 and 10 μ g of biotinylated or unlabeled eRNA 
in 1 ml of DMEM medium for 1 h at 37 °C. Afterwards, the cells were washed twice with PBS and incubated with 
Cy®5-conjugated Streptavidin (Invitrogen Life Technologies) for 1 h at 37 °C. After additional washing steps, cells 
were collected by scratching and the binding of eRNA to cell membrane was analyzed in the Cy®5 channel of the 
flow cytometer. Data were collected using an Accuri C6 flow cytometer (BD Biosciences, Heidelberg, Germany) 
and analyzed by CFlowPlus (BD Biosciences). Gates based on forward and side scatter were set to eliminate cel-
lular debris and cell clusters. A minimum of 2 × 104 cells were analyzed per sample. As an additional control, cells 
incubated with unlabeled eRNA and incubated with Cy®5-conjugated streptavidin were used.
Statistics. The statistical analysis was performed using a GraphPad Prism version 5.02 for Windows 
(GraphPad Software, La Jolla, CA). Differences between groups were assessed using the Student’s t-test. When 
three or more groups were compared, analysis of variance (ANOVA) followed by Tukey’s post hoc test was used. 
Experimental data are presented as mean (± SEM). p value less than 0.05 was considered statistically significant.
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